Want to see FDMT full AI Analyst Report?
FDMT Stock Chart & Stats
$14.91
$0.31(3.08%)
At close: 4:00 PM EDT
$14.91
$0.31(3.08%)
Day’s Range― - ―
52-Week Range$6.96 - $16.93
Previous Close$10.76
Volume531.42K
Average Volume (3M)948.92K
Market Cap
$678.95M
Enterprise Value$612.50M
Total Cash (Recent Filing)$361.33M
Total Debt (Recent Filing)$39.22M
Price to Earnings (P/E)―
Beta0.73
Next Earnings
Nov 11, 2026EPS Estimate
-1.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.72
Shares Outstanding55,244,210
10 Day Avg. Volume976,623
30 Day Avg. Volume948,920
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)0.86
Price to Sales (P/S)5.10
P/FCF Ratio-3.98
Enterprise Value/Market Cap0.90
Enterprise Value/Revenue6.66
Enterprise Value/Gross Profit15.85
Enterprise Value/Ebitda-3.33
Forecast
1Y Price Target
$30.57Price Target Upside105.04% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-4.15
Revenue Forecast (FY)$12.95M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthThe sharp increase in revenue indicates meaningful commercial progress from a small base and provides evidence of growing product or collaboration activity. If sustained, this expanding top line can improve operating leverage and help support continued investment in the company’s gene therapy pipeline.
Low Balance-sheet LeverageVery low leverage limits fixed financial obligations and preserves flexibility while the company advances costly clinical programs. The sizable equity base relative to debt provides a cushion against near-term balance-sheet stress, although it does not eliminate the need to fund ongoing operating losses.
Late-stage 4D-150 ProgressStarting a global Phase 3 trial moves 4D-150 into a later development stage and creates a clearer path toward potential regulatory submissions. The reported two-year efficacy, safety, and injection-burden data provide clinical support for advancing the program in diabetic macular edema.
Bears Say
Persistent Net LossesThe company remains far from profitability despite higher revenue, meaning commercial progress has not yet translated into sustainable earnings. Persistent large losses can consume capital, limit strategic flexibility, and increase dependence on future financing or successful clinical and commercial execution.
Heavy Cash BurnLarge operating and free-cash-flow deficits show that the business is consuming substantial cash to fund development and operations. The increase in annual operating cash outflow from 2025 raises the likelihood that additional funding will be needed if spending and losses remain at similar levels.
Eroding Equity BaseDeclining equity demonstrates that accumulated losses are reducing the company’s capital base over time. Continued erosion can weaken funding flexibility and amplify dilution or financing pressure, particularly while cash burn remains high and the pipeline still requires substantial clinical investment.
4D Molecular Therapeutics News
FDMT FAQ
What was 4D Molecular Therapeutics’s price range in the past 12 months?
4D Molecular Therapeutics lowest stock price was $6.96 and its highest was $16.93 in the past 12 months.
What is 4D Molecular Therapeutics’s market cap?
4D Molecular Therapeutics’s market cap is $678.95M.
When is 4D Molecular Therapeutics’s upcoming earnings report date?
4D Molecular Therapeutics’s upcoming earnings report date is Nov 11, 2026 which is in 22 days.
How were 4D Molecular Therapeutics’s earnings last quarter?
4D Molecular Therapeutics released its earnings results on Aug 13, 2026. The company reported -$1.04 earnings per share for the quarter, missing the consensus estimate of -$1.017 by -$0.023.
Is 4D Molecular Therapeutics overvalued?
According to Wall Street analysts 4D Molecular Therapeutics’s price is currently Undervalued.
Does 4D Molecular Therapeutics pay dividends?
4D Molecular Therapeutics does not currently pay dividends.
What is 4D Molecular Therapeutics’s EPS estimate?
4D Molecular Therapeutics’s EPS estimate is -1.05.
How many shares outstanding does 4D Molecular Therapeutics have?
4D Molecular Therapeutics has 55,244,210 shares outstanding.
What happened to 4D Molecular Therapeutics’s price movement after its last earnings report?
4D Molecular Therapeutics reported an EPS of -$1.04 in its last earnings report, missing expectations of -$1.017. Following the earnings report the stock price went up 4.635%.
Which hedge fund is a major shareholder of 4D Molecular Therapeutics?
Currently, no hedge funds are holding shares in FDMT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
4D Molecular Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$30.57 (105.04% Upside)
$30.57 (105.04% Upside)
Blogger Sentiment
Bullish
FDMT Sentiment 60%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 56.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.1%
Last 30 Days ▲ 10.0%
Last 30 Days ▲ 10.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
24.89%
12-Months-Change
Fundamentals
Return on Equity
-41.33%
Trailing 12-Months
Asset Growth
4.01%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
4D Molecular Therapeutics
4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company that engineers therapeutic agents by leveraging its proprietary adeno-associated virus (AAV) vector technology. The company's developmental efforts are concentrated across a trio of therapeutic fields: ophthalmology (eye conditions), cardiology (heart ailments), and pulmonology (respiratory disorders). Within its active pipeline, three specific product candidates have advanced into clinical trial phases, all currently undergoing Phase 1/2 clinical assessment: 4D-125 is being evaluated for the treatment of X-linked retinitis pigmentosa. 4D-110 targets choroideremia. 4D-310 is focused on addressing Fabry disease. Beyond these, two Investigational New Drug (IND) candidates are in development: 4D-150, aimed at combating wet age-related macular degeneration, and 4D-710, designed to tackle cystic fibrosis lung disease. To advance its mission, 4D Molecular Therapeutics, Inc. actively engages in research and development partnerships with entities such as uniQure, CRF, Roche, and CFF. The firm commenced operations in 2013 and maintains its headquarters in Emeryville, California.
FDMT Stock 12 Month Forecast
Average Price Target
$30.57
▲(105.04% Upside)
Technical Analysis
Assembly Biosciences
―
Korro Bio
―
Design Therapeutics
―
Immuneering
―
Aura Biosciences Inc
―
Ownership Overview
1.64% Insiders
12.47% Mutual Funds
0.16% Other Institutional Investors
68.43% Public Companies and
Individual Investors